HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $34 Price Target

Roivant Sciences Ltd.

Roivant Sciences Ltd.

ROIV

0.00

HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ: ROIV) with a Buy and maintains $34 price target.